GCO reports a narrower-than-expected loss per share and sales beat in second-quarter fiscal 2025. E-commerce comps rose 8%.
Vous n'êtes pas connecté
Allogene's (ALLO) second-quarter earnings beat estimates but sales miss the mark. It expects to submit a regulatory filing with the FDA for its lead pipeline drug in large B-cell lymphoma indication by 2027.
GCO reports a narrower-than-expected loss per share and sales beat in second-quarter fiscal 2025. E-commerce comps rose 8%.
GCO reports a narrower-than-expected loss per share and sales beat in second-quarter fiscal 2025. E-commerce comps rose 8%.
FL Q2 revenues beat estimates. Comparable sales increase 2.6% year over year, driven by 5.2% comps growth in global Foot Locker and Kids Foot Locker...
AEO posts revenue miss in second-quarter fiscal 2024. It anticipates operating income to be in the range of $120-$125 million for the fiscal third...
Academy Sports' second-quarter fiscal 2024 results reflect soft demand trends due to macroeconomic uncertainties.
VIRC's second-quarter fiscal 2024 results benefit from higher factory output and improved operating efficiencies, along with a significant...
VIRC's second-quarter fiscal 2024 results benefit from higher factory output and improved operating efficiencies, along with a significant...
ZUMZ's fiscal Q2 results are aided by a strong North America business, reflecting comps growth in June and July, particularly driven by the onset of...
SLNO stock gains 6.3% as FDA accepts regulatory filing for lead candidate, DCCR, to treat hyperphagia associated with PWS under Priority Review.
LULU Q2 results reflect soft sales trends on continued weakness in the Americas, wherein comps dipped 3%. Its expense control aids EPS.